ABBA CORD Trial: dCBT with Abatacept for Graft vs. Host Disease Prevention
Phase 2
20
about 3.7 years
18–65
1 site in OH
About this study
This trial is testing if adding abatacept to tacrolimus and mycophenolate mofetil (MMF) can prevent or reduce acute graft versus host disease (aGVHD) after a cord blood transplant in people with certain types of cancer. Participants will receive treatment, including a cord blood transplant and radiation therapy.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Double Umbilical Cord Transplant
- 2.Receive Total Body Irradiation
- 3.Take Abatacept
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
abatacept, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine, Immunological Agents (Enzyme Inhibitors), tacrolimus, thiotepa
injection, intravenous, infusion, injection (Injection)
Secondary: Assessment of aGVHD biomarker REG3α, Assessment of aGVHD biomarker ST2, Disease free survival, Incidence of chronic GVHD, Non-relapse mortality, Overall Survival
radiation
Oncology